Larimar Therapeutics
LRMR
NASDAQ
IPO2020
about LRMR
Larimar Therapeutics focuses on developing innovative therapies for rare and debilitating diseases, primarily advancing its lead oral JAK1/2 inhibitor to address unmet needs in inflammation and immunity-related conditions.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $3.66 | $6.10 | $3.65 | $306.60M | 55.31M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.61 | n/a | n/a | 0% | 0% | 0% |